Amundi Acquires 21,783 Shares of Core Laboratories Inc. (NYSE:CLB)

Amundi grew its holdings in Core Laboratories Inc. (NYSE:CLB - Free Report) by 194.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 32,968 shares of the oil and gas company's stock after acquiring an additional 21,783 shares during the quarter. Amundi owned 0.07% of Core Laboratories worth $600,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the business. Disciplined Growth Investors Inc. MN grew its position in shares of Core Laboratories by 26.7% in the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 5,653,591 shares of the oil and gas company's stock valued at $104,761,000 after purchasing an additional 1,192,871 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Core Laboratories in the fourth quarter valued at approximately $6,760,000. Eagle Asset Management Inc. bought a new stake in shares of Core Laboratories during the third quarter worth $3,531,000. Fisher Asset Management LLC raised its holdings in shares of Core Laboratories by 19.5% during the third quarter. Fisher Asset Management LLC now owns 990,267 shares of the oil and gas company's stock worth $18,350,000 after acquiring an additional 161,278 shares during the period. Finally, Rice Hall James & Associates LLC bought a new stake in Core Laboratories in the 4th quarter valued at $1,960,000. Institutional investors and hedge funds own 97.81% of the company's stock.

Core Laboratories Stock Up 1.7 %

CLB stock traded up $0.26 during mid-day trading on Monday, reaching $15.59. The company had a trading volume of 222,728 shares, compared to its average volume of 358,193. The company has a market capitalization of $729.94 million, a price-to-earnings ratio of 23.62, a PEG ratio of 0.99 and a beta of 2.38. Core Laboratories Inc. has a 52 week low of $12.95 and a 52 week high of $25.13. The stock has a 50 day simple moving average of $16.79 and a two-hundred day simple moving average of $18.17. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.32 and a quick ratio of 1.71.

Remove Ads

Core Laboratories (NYSE:CLB - Get Free Report) last released its earnings results on Wednesday, January 29th. The oil and gas company reported $0.23 earnings per share for the quarter, meeting the consensus estimate of $0.23. Core Laboratories had a net margin of 5.99% and a return on equity of 16.24%. As a group, equities analysts predict that Core Laboratories Inc. will post 0.96 earnings per share for the current fiscal year.

Core Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Monday, February 10th were issued a $0.01 dividend. The ex-dividend date of this dividend was Monday, February 10th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.26%. Core Laboratories's payout ratio is 6.06%.

Analyst Ratings Changes

Separately, Citigroup raised Core Laboratories from a "sell" rating to a "neutral" rating and upped their price target for the stock from $15.00 to $16.00 in a research report on Wednesday, March 12th. One investment analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $17.50.

About Core Laboratories

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.